27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
Argus says Galapagos ADR (NYSE: GLPG) though not covered by the firm, warrants attention following Gilead (NASDAQ: GILD) news of a collaboration deal announced on Friday.
Argus sees Gilead cashflow helping to expand the drug pipeline.
The advantage of fibfotnib over alternatives is that it is a pill, no injection required. If approved, Argus believes the drug could hit the market in 2019 as a viable alternative to Humira's offering and other anti-TNF drugs.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!